SI2616076T1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- SI2616076T1 SI2616076T1 SI201130966A SI201130966A SI2616076T1 SI 2616076 T1 SI2616076 T1 SI 2616076T1 SI 201130966 A SI201130966 A SI 201130966A SI 201130966 A SI201130966 A SI 201130966A SI 2616076 T1 SI2616076 T1 SI 2616076T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38354110P | 2010-09-16 | 2010-09-16 | |
| EP11825920.9A EP2616076B1 (en) | 2010-09-16 | 2011-09-15 | Pharmaceutical compositions |
| PCT/US2011/051713 WO2012037320A2 (en) | 2010-09-16 | 2011-09-15 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2616076T1 true SI2616076T1 (en) | 2016-11-30 |
Family
ID=45832235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130966A SI2616076T1 (en) | 2010-09-16 | 2011-09-15 | Pharmaceutical compositions |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US20130171214A1 (en) |
| EP (1) | EP2616076B1 (en) |
| JP (1) | JP6231385B2 (en) |
| KR (1) | KR101938662B1 (en) |
| CN (1) | CN103547266B (en) |
| AU (1) | AU2011302030B2 (en) |
| BR (1) | BR112013005907B1 (en) |
| CA (1) | CA2810524C (en) |
| CL (1) | CL2013000715A1 (en) |
| CY (1) | CY1118279T1 (en) |
| DK (1) | DK2616076T3 (en) |
| EA (1) | EA024924B1 (en) |
| ES (1) | ES2594557T3 (en) |
| HR (1) | HRP20161280T1 (en) |
| HU (1) | HUE031336T2 (en) |
| IL (1) | IL225028A (en) |
| LT (1) | LT2616076T (en) |
| ME (1) | ME02520B (en) |
| MX (1) | MX346193B (en) |
| PL (1) | PL2616076T3 (en) |
| PT (1) | PT2616076T (en) |
| RS (1) | RS55222B1 (en) |
| SI (1) | SI2616076T1 (en) |
| SM (1) | SMT201600350B (en) |
| TW (1) | TWI577377B (en) |
| UA (1) | UA108250C2 (en) |
| WO (1) | WO2012037320A2 (en) |
| ZA (1) | ZA201301766B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3387B1 (en) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | Derivatives of betulin |
| SG11201503807TA (en) * | 2012-12-14 | 2015-06-29 | Glaxosmithkline Llc | Pharmaceutical compositions |
| WO2015108945A2 (en) | 2014-01-14 | 2015-07-23 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| EP3110422A4 (en) * | 2014-02-24 | 2017-09-06 | Board of Regents of the University of Nebraska | Compositions and methods for the delivery of therapeutics |
| CA2961528A1 (en) * | 2014-09-26 | 2016-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions |
| WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| TN2017000232A1 (en) * | 2014-12-20 | 2018-10-19 | Troikaa Pharmaceuticals Ltd | Injectable formulations of paracetamol |
| WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| US11077050B2 (en) | 2017-03-24 | 2021-08-03 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
| RS65207B1 (en) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv | Long-acting formulations of bedaquiline |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | COMBINATION THERAPY |
| EP3737359A4 (en) | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS |
| US11458136B2 (en) | 2018-04-09 | 2022-10-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| MY207622A (en) | 2018-10-22 | 2025-03-06 | Univ Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN118873676A (en) | 2018-11-29 | 2024-11-01 | 内布拉斯加大学董事会 | Antiviral prodrugs and their nanoparticle preparations |
| CN109646440B (en) * | 2019-01-11 | 2021-04-20 | 山东省农业科学院奶牛研究中心 | Application of Cabotegravir in the preparation of anti-bovine infectious rhinotracheitis drug |
| SI3938047T1 (en) | 2019-03-22 | 2022-10-28 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| IL293566A (en) * | 2019-12-09 | 2022-08-01 | Viiv Healthcare Co | Pharmaceutical compositions comprising cabotegravir |
| WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| JP2023532981A (en) * | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ．ベー． | long-acting formulation |
| WO2022008643A1 (en) * | 2020-07-09 | 2022-01-13 | Janssen Pharmaceutica Nv | Long-acting formulations |
| EP4208169A1 (en) * | 2020-09-01 | 2023-07-12 | VIIV Healthcare Company | Combination of cabotegravir and levonorgestrel |
| KR20230079137A (en) | 2020-09-30 | 2023-06-05 | 길리애드 사이언시즈, 인코포레이티드 | Crosslinked Tricyclic Carbamoylpyridone Compounds and Uses Thereof |
| WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
| PT4196479T (en) | 2021-01-19 | 2024-01-03 | Gilead Sciences Inc | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND THEIR USES |
| TWI856796B (en) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| CN118121552A (en) * | 2022-12-01 | 2024-06-04 | 浙江萃泽医药科技有限公司 | Injectable pharmaceutical composition and preparation method and application thereof |
| WO2025181723A1 (en) | 2024-03-01 | 2025-09-04 | ViiV Healthcare UK (No.3) Limited | Dosing regimen |
| CN120424092B (en) * | 2025-07-02 | 2025-09-12 | 中国人民解放军军事科学院军事医学研究院 | Bunyavirus inhibitor and its preparation method and use |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1215599A (en) * | 1958-06-27 | 1960-04-19 | Rhone Poulenc Sa | New derivatives of iminodibenzyl substituted for nitrogen by a piperazine chain and their preparation |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| CA2224008C (en) | 1995-06-07 | 2009-08-18 | Trimeris, Inc. | The treatment of hiv and other viral infections using combinatorial therapy |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6066292A (en) * | 1997-12-19 | 2000-05-23 | Bayer Corporation | Sterilization process for pharmaceutical suspensions |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| JP5160005B2 (en) * | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | Sustained release formulation |
| IL166156A0 (en) * | 2002-07-09 | 2006-01-15 | Point Therapeutics Inc | Boroproline compound combination therapy |
| DE60309731T2 (en) * | 2002-08-21 | 2007-06-28 | Pharmacia Corp. | INJECTABLE PHARMACEUTICAL SUSPENSION IN A TWO-CHAMBERED PHIO |
| CA2523035C (en) | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
| CA2554246A1 (en) | 2004-01-29 | 2005-08-11 | Baxter International Inc. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| US7985222B2 (en) | 2004-04-21 | 2011-07-26 | Medshape Solutions, Inc. | Osteosynthetic implants and methods of use and manufacture |
| EP1879890A1 (en) | 2005-04-25 | 2008-01-23 | Janssen Pharmaceutica N.V. | Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester |
| US8129385B2 (en) * | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| WO2007053189A2 (en) * | 2005-06-01 | 2007-05-10 | Northwestern University | Compositions and methods for altering immune function |
| EP1904052A4 (en) | 2005-06-17 | 2008-12-10 | Hospira Australia Pty Ltd | Liquid pharmaceutical formulations of docetaxel |
| US20070001094A1 (en) | 2005-06-29 | 2007-01-04 | Micron Technology, Inc. | Infrared filter for imagers |
| PL1981506T6 (en) * | 2006-01-20 | 2021-07-12 | Janssen Sciences Ireland Uc | Long term treatment of hiv- infection with tcm278 |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| SI3366278T1 (en) | 2006-06-23 | 2024-12-31 | Janssen Sciences Ireland Unlimited Company | Aqueous suspensions of tmc278 |
| DK2175857T3 (en) * | 2007-07-12 | 2013-12-02 | Janssen R & D Ireland | Crystalline Form of (E) 4 - [[4 - [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRIL |
| SI2234617T2 (en) * | 2007-12-19 | 2025-05-30 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
| TWI532498B (en) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | Combination and method for subcutaneous administration of immunoglobulin and hyaluronic acid |
| WO2009128918A1 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| SG192550A1 (en) * | 2008-07-25 | 2013-08-30 | Viiv Healthcare Co | Chemical compounds |
| EP2376453B1 (en) | 2008-12-11 | 2019-11-20 | VIIV Healthcare Company | Intermediates for carbamoylpyridone hiv integrase inhibitors |
| EP2376080B1 (en) | 2008-12-11 | 2017-09-13 | Shionogi&Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| WO2011017395A1 (en) | 2009-08-04 | 2011-02-10 | Glaxosmithkline Llc | Chemical compounds |
| US20110152303A1 (en) | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Chemical Compounds |
-
2011
- 2011-09-14 TW TW100133064A patent/TWI577377B/en active
- 2011-09-15 SI SI201130966A patent/SI2616076T1/en unknown
- 2011-09-15 AU AU2011302030A patent/AU2011302030B2/en active Active
- 2011-09-15 WO PCT/US2011/051713 patent/WO2012037320A2/en not_active Ceased
- 2011-09-15 EA EA201390233A patent/EA024924B1/en unknown
- 2011-09-15 DK DK11825920.9T patent/DK2616076T3/en active
- 2011-09-15 CA CA2810524A patent/CA2810524C/en active Active
- 2011-09-15 EP EP11825920.9A patent/EP2616076B1/en active Active
- 2011-09-15 ME MEP-2016-192A patent/ME02520B/en unknown
- 2011-09-15 JP JP2013529316A patent/JP6231385B2/en active Active
- 2011-09-15 PT PT118259209T patent/PT2616076T/en unknown
- 2011-09-15 IL IL225028A patent/IL225028A/en active IP Right Grant
- 2011-09-15 RS RS20160826A patent/RS55222B1/en unknown
- 2011-09-15 CN CN201180044588.5A patent/CN103547266B/en active Active
- 2011-09-15 KR KR1020137009569A patent/KR101938662B1/en active Active
- 2011-09-15 MX MX2013003037A patent/MX346193B/en active IP Right Grant
- 2011-09-15 LT LTEP11825920.9T patent/LT2616076T/en unknown
- 2011-09-15 BR BR112013005907-9A patent/BR112013005907B1/en active IP Right Grant
- 2011-09-15 UA UAA201303057A patent/UA108250C2/en unknown
- 2011-09-15 HR HRP20161280TT patent/HRP20161280T1/en unknown
- 2011-09-15 HU HUE11825920A patent/HUE031336T2/en unknown
- 2011-09-15 PL PL11825920T patent/PL2616076T3/en unknown
- 2011-09-15 US US13/823,316 patent/US20130171214A1/en not_active Abandoned
- 2011-09-15 ES ES11825920.9T patent/ES2594557T3/en active Active
-
2013
- 2013-03-07 ZA ZA2013/01766A patent/ZA201301766B/en unknown
- 2013-03-15 CL CL2013000715A patent/CL2013000715A1/en unknown
-
2016
- 2016-10-04 SM SM201600350T patent/SMT201600350B/en unknown
- 2016-10-04 CY CY20161100985T patent/CY1118279T1/en unknown
- 2016-10-13 US US15/292,394 patent/US11224597B2/en active Active
-
2021
- 2021-12-10 US US17/547,682 patent/US20220096469A1/en not_active Abandoned
-
2024
- 2024-05-31 US US18/679,621 patent/US12138264B2/en active Active
- 2024-10-01 US US18/903,140 patent/US20250017924A1/en not_active Abandoned
- 2024-10-01 US US18/903,119 patent/US20250017923A1/en not_active Abandoned
-
2025
- 2025-05-15 US US19/208,707 patent/US20250268893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201300458B (en) | C-met-modulator pharmaceutical compositions | |
| IL245326A0 (en) | Pharmaceutical composition | |
| ZA201301766B (en) | Pharmaceutical compositions | |
| IL223535A (en) | Solid pharmaceutical compositions | |
| ZA201207670B (en) | Pharmaceutical compositions | |
| PL2619182T3 (en) | Pharmaceutical composition | |
| IL225457A0 (en) | Pharmaceutical composition | |
| ZA201300718B (en) | Pharmaceutical compositions | |
| HUE050788T2 (en) | Novel pharmaceutical composition | |
| PT2579858E (en) | Ivabradine-containing pharmaceutical composition | |
| ZA201301920B (en) | Pharmaceutical composition | |
| GB201010453D0 (en) | Pharmaceutical composition | |
| ZA201303223B (en) | Pharmaceutical compositions | |
| ZA201303177B (en) | Pharmaceutical compositions | |
| IL226554A (en) | Pharmaceutical compositions comprising alisporivir | |
| IL221501A (en) | Pharmaceutical composition comprising myramistin | |
| EP2560678A4 (en) | Pharmaceutical compositions | |
| GB201001911D0 (en) | Pharmaceutical composition | |
| ZA201303732B (en) | Pharmaceutical compositions | |
| GB201008590D0 (en) | Pharmaceutical compositions | |
| GB201005403D0 (en) | Novel pharmaceutical compositions | |
| GB201019775D0 (en) | Pharmaceutical composition | |
| HU1000006D0 (en) | Improved pharmaceutical composition |